Sagimet Biosciences Inc. Series A Common Stock (SGMT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $11.09 (-0.72%), Market cap $0.43B, 52-week low–high $3.22 ~ $10.24.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagi
Financial statements, price targets, institutional (13F) holdings and related news for Sagimet Biosciences Inc. Series A Common Stock are updated in real time on BlackAll Trade.
Sagimet Biosciences Inc. Series A Common Stock trades at $11.09 (-0.72%). Real-time quotes and charts are available on BlackAll Trade.
Sagimet Biosciences Inc. Series A Common Stock has a market cap of about $0.43B.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctio